The scenarios provided by the AMA offer best coding practices that can assist payors in applying the best flexibility to physicians in providing patient care during this public health crisis. Information provided for each scenario is based on who is performing the service, applicable CPT codes, COVID-19 focused ICD-10 CM codes, the place of service, and other additional data. Be advised that this guide does not dictate payer reimbursement policy and does not substitute for the professional judgment of the practitioner performing a procedure, who remains responsible for correct coding.
With INDICAID® Covid-19 Rapid Antigen Test at the helm as one of the world’s leading antigen tests, we have confidence that Medicare, Medicaid, and medical insurance will cover it under US FDA Emergency Use Authorization (EUA). INDICAID® offers easy, affordable, and reliable mass testing for government agencies, businesses, healthcare providers, and consumers, mitigating the spread and transmission of the virus and allowing the country to get back to work and play.